Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 10/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | CYBB | P04839 | 1/20 | 0.37 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24334134 | 1.00 | NCF1 (0.38) | NCF1DRD2CYBBNOX5DRD4 | |
| SCHEMBL26972310 | 0.98 | NCF1 (0.38) | NCF1DRD2CYBBNOX5DRD4 | |
| SCHEMBL18194474 | 0.92 | NCF1 (0.40) | NCF1DRD2CYBBNOX5DRD4 | |
| SCHEMBL25494738 | 0.88 | DRD2 (0.42) | NCF1DRD2CYBBNOX5DRD4 | |
| SCHEMBL24372151 | 0.88 | NCF1 (0.43) | NCF1CYBBNOX5 | |
| SCHEMBL25494745 | 0.88 | DRD2 (0.42) | NCF1DRD2CYBBNOX5DRD4 | |
| SCHEMBL25494740 | 0.88 | DRD2 (0.42) | NCF1DRD2CYBBNOX5DRD4 | |
| SCHEMBL24334135 | 0.88 | DRD2 (0.39) | NCF1DRD2CYBBNOX5DRD4 | |
| SCHEMBL19576264 | 0.87 | NOTUM (0.39) | NCF1DRD2CYBBNOX5DRD4 | |
| SCHEMBL26432992 | 0.87 | GBA1 (0.45) | NCF1DRD2CYBBNOX5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340000-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20230340000-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20230279041-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11692001-B2 | Functionalized n-acetylgalactosamine analogs | HONGENE BIOTECH CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11692001-B2 | Functionalized n-acetylgalactosamine analogs | HONGENE BIOTECH CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340000-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | FUT6, CSGALNACT1, GALNT6 | NCF1 1362/4885DRD2 4575/4885CYBB 1002/4885 |
| US-11692001-B2 | Functionalized n-acetylgalactosamine analogs | FUT6, CSGALNACT1, GALNT6 | NCF1 1362/4885DRD2 4575/4885CYBB 1002/4885 |
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | SLC10A2, FABP2, SLC10A1 | NCF1 1426/4885DRD2 1423/4885CYBB 2776/4885 |
| US-20230279041-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | FUT6, CSGALNACT1, GALNT6 | NCF1 1362/4885DRD2 4575/4885CYBB 1002/4885 |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | SLC10A1, SLC10A2, SLC9A2 | NCF1 716/4885DRD2 2090/4885CYBB 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.